MSB 11.8% $1.57 mesoblast limited

“WHO continues to review the evidence on antibody responses to...

  1. 2,743 Posts.
    lightbulb Created with Sketch. 1014
    “WHO continues to review the evidence on antibody responses to SARS-CoV-2 infection.2-17 Most of these studies show that people who have recovered from infection have antibodies to the virus. However, some of these people have very low levels of neutralizing antibodies in their blood,4suggesting that cellular immunity may also be critical for recovery. As of 24 April 2020, no study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to subsequent infection by this virus in humans.”

    https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.57
Change
-0.210(11.8%)
Mkt cap ! $1.792B
Open High Low Value Volume
$1.72 $1.74 $1.52 $15.63M 9.716M

Buyers (Bids)

No. Vol. Price($)
1 5127 $1.57
 

Sellers (Offers)

Price($) Vol. No.
$1.57 39613 3
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.